CA-ENEVATE
Enevate , a pioneer in advanced silicon-dominant lithium-ion (Li-ion) battery technology capable of extreme fast charging for electric vehicles (EVs), announced its new 4th generation technology optimized for high volume commercialization and manufacturing at gigafactory scale. Enevate is providing a solution to a difficult problem for automotive OEMs and EV battery manufacturers – providing extreme fast charging with high energy density and at lower material cost than conventional Li-ion batteries, while being compatible with existing battery fabrication facilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200114005035/en/
The new XFC-Energy™ technology achieves 5-minute charging to 75 percent capacity with 800 Wh/L cell energy density. Today’s conventional large-format Li-ion EV cells are at 500-600 Wh/L and typically take over 1 hour to charge.
“Mass EV adoption by consumers and fleet owners will depend to a large degree on advanced battery technology that will remove current barriers to entry such as long charging times and limited range,” said Christian Noske , Chairman of Alliance Ventures (Renault-Nissan-Mitsubishi). “Enevate is a key enabler for electric vehicles that are affordable, easy and quick to charge, and clean.”
Dr. John Goodenough , a recipient of the 2019 Nobel Prize in chemistry for groundbreaking work in the development of lithium-ion batteries and who has served on Enevate’s Advisory Board since 2010, added: “I salute the Enevate team for reaching this next important step in fulfilling the company’s mission to develop and commercialize innovative battery technologies to accelerate the adoption of electrified mobility.”
Enevate’s 4th generation XFC-Energy technology stands to be a game-changer for the EV industry, providing a path to produce extreme fast-charge EV batteries at low cost and high-volume production. Enevate is currently working with multiple automotive OEMs and EV battery manufacturers to commercialize its technology for 2024-2025 model year EVs, utilizing existing manufacturing infrastructure with minimal investment required, a core goal of its development.
Enevate’s 4th generation is the latest result of over 74 million hours of battery cell testing by Enevate’s scientists, 1 million meters of electrodes produced in the company’s R&D pilot line, and 2 billion test datapoints.
Enevate Founder and Chief Technology Officer Dr. Benjamin Park noted that Enevate’s XFC-Energy technology has been designed for large-format pouch, prismatic and cylindrical EV cells, utilizing its pure silicon anode paired with nickel-rich NCA, NCM and NCMA advanced cathodes.
“Enevate’s extreme fast charge technology enables a future where gas stations become drive-through EV charging stations – a win-win for consumers and the environment as electric vehicles replace those using gasoline,” Dr. Park said. “Enevate’s technology will help close the usability gap between today’s EVs and gas cars.”
Dr. Park will be discussing Enevate’s technology on January 15 at the Advanced Automotive Battery Conference in Weisbaden, Germany, in a presentation titled “Charging Ahead: Commercializing Fast-Charge Si-Dominant Li-ion Cells for EVs.”
XFC-Energy Technology Technical Details
- Cell technology scalable for large-format pouch, prismatic and cylindrical EV cells suitable for various battery module and pack architectures. Achieves 800 Wh/L and 340 Wh/kg in large-format EV cells.
- Pure silicon-dominant anode technology tunable with 10-60µm thickness and 1000-2000mAh/g that can be paired with NCA, NCM811, NCMA, low-cobalt, or other advanced cathode technologies.
- Continuous roll-to-roll anode manufacturing processes designed and capable of achieving over 80 meters per minute electrode production, over 10 GWh per electrode production line, with pure silicon anode rolls greater than 1 meter wide and longer than 5 kilometers in length sufficient for high volume gigafactory production, among other features.
- Lower anode material cost (dollar per kWh) than conventional and synthetic graphite.
- Transformative performance improvement, with five-minute charge to 75 percent of battery capacity, and, when paired with a high-nickel cathode, capable of over 1000 cycles using an EV drive cycle test and operation at -20˚C and below temperatures.
- Bottom line: Five-minute extreme fast charging, high energy density, low temperature operation, low cost and superior safety.
ABOUT ENEVATE (www.enevate.com)
Enevate develops and licenses advanced silicon-dominant Li-ion battery technology for electric vehicles (EVs), with a vision to charging EVs as fast as refueling gas cars and accelerating their mass adoption. With a portfolio of more than 200 patents issued and in process, Enevate’s pioneering advancements in silicon-dominant anodes and cells have resulted in battery technology that features five-minute extreme fast charging with high energy density, low temperature operation for cold climates, low cost and safety advantages over conventional Li-ion batteries.
Enevate’s vision is to develop and propagate EV battery technology that contributes to a clean and sustainable environment. The Irvine, California-based company has raised over $110 million from investors including Renault-Nissan-Mitsubishi (Alliance Ventures), LG Chem, Samsung, Mission Ventures, Draper Fisher Jurvetson, Tsing Capital, Infinite Potential Technologies, Presidio Ventures – a Sumitomo Corporation company, Lenovo, CEC Capital and Bangchak. Enevate®, the Enevate logo, XFC-Energy™, HD-Energy®, and eBoost® are registered trademarks of Enevate Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
